Combining Radiotherapy and Immunotherapy in Head and Neck Cancer.

Biomedicines · 2023 · PMC10452591 · PMID 37626594

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The trial enrolled 804 patients, and on final analysis for primary end point (efficacy boundary survival), the results showed a favorable trend, but no statistically significant benefit for pembrolizumab arm HR 0.83 (05% CI, 0.68–1.03).

also in 377 other papers

showed a trendno p-value reported

On subgroup analysis, patients with tumors that had PD-L1 high expression (CPS ≤ 25%) showed a trend of potential benefit, with an HR of 0.59 (95% CI, 0.28–1.22) [ 35 ].

also in 15,197 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.